Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296764 · ClinicalTrials.gov registry record
Characterization of Angelman Syndrome
A clinical trial of Angelman Syndrome, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 302
- Enrollment target
- 6
- Study locations
NCT00296764 is a study of Angelman Syndrome that has completed, run by Boston Children's Hospital. The registered enrollment target is 302 participants, above the 99-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (205% higher). The trial reports 6 study locations across 6 states.
The verdict
NCT00296764, a study of Angelman Syndrome, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 302 participants
- Enrollment target
- 6
- Study locations
Study Summary
Angelman Syndrome (AS) is a developmental disorder that is caused by a deficiency of a maternally transmitted gene. It is inherited at birth, and affects movement, speech, and social demeanor. This study will gain a better understanding of the disease progression and clinical features of AS by observing children with AS over an extended period of time.
Conditions Studied
Study Locations (6)
California
- Rady Children's Hospital San Diego - San Diego
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Cincinnati Children's Hospital and Medical Center - Cincinnati
South Carolina
- Greenwood Genetic Center - Greenwood
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2006-02 |
| Est. Completion | 2014-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296764
The ClinicalTrials.gov registry entry for NCT00296764 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (205% higher). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Angelman Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT00296764 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT00296764 about?
NCT00296764 is a clinical study titled "Characterization of Angelman Syndrome". Angelman Syndrome (AS) is a developmental disorder that is caused by a deficiency of a maternally transmitted gene. It is inherited at birth, and affects movement, speech, and social demeanor. This study will gain a better understanding of the disease progression and clinical features of AS by obser...
What is the current status of trial NCT00296764?
This trial is currently completed. The enrollment target is 302 participants. The study started on 2006-02. Estimated completion is 2014-08.
What conditions does trial NCT00296764 study?
This clinical trial studies the following conditions: Angelman Syndrome.
Who is sponsoring clinical trial NCT00296764?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00296764 being conducted?
This trial has 6 study locations across California, Massachusetts, Ohio, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angelman Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Angelman Syndrome Natural History Study
RECRUITING
-
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
RECRUITING · Phase 3
-
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
RECRUITING · Phase 1
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RECRUITING · Phase 2
-
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.